Skip to the page

Data / Drug companies / Azurity Pharmaceuticals, Inc.

Azurity Pharmaceuticals, Inc.: 56 products in the FDA NDC directory, labeler code 24338

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Azurity Pharmaceuticals, Inc. (labeler code 24338) lists 56 products in the FDA National Drug Code Directory, covering 23 finished drugs by generic name. By type: 54 prescription drugs, 2 over the counter drugs. Its main marketing category is new drug applications (NDA). The newest product started marketing on August 11, 2026.

The request: Watch Azurity Pharmaceuticals, Inc. (FDA labeler code 24338): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
24338
Products in commercial distribution
56
Packages
64
Finished drugs by generic name
23
Prescription products
54
Over the counter products
2
Controlled substance products
Schedule II 14, Schedule III 2
Flagged as original packager
55 of 55 products that carry the flag
Started marketing in the last 12 months
11
Earliest marketing start
April 18, 2011
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
New drug applications (NDA)3867.9%
Generic drugs (ANDA)1832.1%

Products by type

TypeProductsShare
Prescription drugs5496.4%
Over the counter drugs23.6%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Tablet1730.4%
Solution1017.9%
Injection47.1%
Tablet, film coated35.4%
Suspension35.4%
Tablet, delayed release35.4%
Capsule, gelatin coated35.4%
Injection, solution23.6%
Granule, for suspension23.6%
Solution, concentrate23.6%
Lotion23.6%
Kit23.6%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Ivermectin24338-119LotionGeneric drugs (ANDA)August 11, 2026
GoLYTELY24338-236Powder, for solutionNew drug applications (NDA)April 17, 2026
Suflave24338-550KitNew drug applications (NDA)April 1, 2026
Sutab24338-201TabletNew drug applications (NDA)April 1, 2026
SUPREP Bowel Prep24338-177Solution, concentrateNew drug applications (NDA)April 1, 2026
SUPREP Bowel Prep24338-175Solution, concentrateNew drug applications (NDA)April 1, 2026
Arynta24338-162SolutionNew drug applications (NDA)March 20, 2026
Arynta24338-160SolutionNew drug applications (NDA)March 20, 2026
Arynta24338-109SolutionNew drug applications (NDA)March 20, 2026
Arynta24338-103SolutionNew drug applications (NDA)March 20, 2026
Arynta24338-019SolutionNew drug applications (NDA)March 20, 2026
Gleostine24338-342Capsule, gelatin coatedNew drug applications (NDA)October 24, 2025
Gleostine24338-341Capsule, gelatin coatedNew drug applications (NDA)October 24, 2025
Gleostine24338-340Capsule, gelatin coatedNew drug applications (NDA)October 24, 2025
Javadin24338-115SolutionNew drug applications (NDA)October 23, 2025
FeraBright24338-510InjectionNew drug applications (NDA)October 20, 2025
FeraBright24338-310InjectionNew drug applications (NDA)October 20, 2025
Widaplik24338-003TabletNew drug applications (NDA)October 20, 2025
Widaplik24338-002TabletNew drug applications (NDA)October 20, 2025
Widaplik24338-001TabletNew drug applications (NDA)October 20, 2025
Xifyrm24338-153InjectionNew drug applications (NDA)June 5, 2025
Vivimusta24338-270InjectionNew drug applications (NDA)April 1, 2025
Brynovin24338-017SolutionNew drug applications (NDA)April 1, 2025
Danziten24338-155TabletNew drug applications (NDA)November 30, 2024
Danziten24338-154TabletNew drug applications (NDA)November 30, 2024

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.